^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Uterine Corpus Leiomyosarcoma |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Published date:
11/17/2022
Excerpt:
In the BRCA1/2 cohort, responses were more frequent (OR rate, 30.3%; 95% CI, 22.2%-39.3%, including 8 complete responses [6.7%]) and more durable (median duration of response: 10.9 months [95% CI, 6.2 months to not estimable]) in tumor types associated with increased heritable cancer risk (ie, BRCA1/2-associated cancer types, such as ovarian, breast, prostate, and pancreatic cancers) and in uterine leiomyosarcoma (objective response in 3 of 3 patients and with ongoing responses greater than 24 months) compared with non-BRCA-associated cancer types.
DOI:
10.1001/jamaoncol.2022.5218
Trial ID:
